This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.
Click here to view current CME activities.
Clinicians are faced with significant challenges in the care of patients with metastatic breast cancer. The disease must be controlled, but therapeutic toxicity may compromise the patient’s quality of life. In addition, many women recur after previous treatment with adjuvant anthracyclines and taxanes, and finding an effective agent in the setting of anthracycline and taxane resistance is difficult.
Novel treatment strategies and informed drug development may facilitate ways of overcoming resistance. An active area of drug development is therapies that target the microtubule. Epothilones work by stabilizing tubule polymerization, while the vinca alkaloids and eribulin mesylate work by destabilizing polymerization. In each case, cell mitosis is disrupted and apoptosis occurs.
In Targeting the Microtubule: A Novel Approach to Treating Metastatic Breast Cancer, we will begin with an overview of the challenges associated with treating resistant or refractory metastatic breast cancer. The discussion will expand to include efficacy and safety data of currently available epothilones and emerging microtubule-targeting agents. Case studies will conclude the webcast, highlighting the fact that our application of these data is always in the setting of real patients presenting themselves to us for care
- Challenges in Treating Resistant/Refractory Metastatic Breast Cancer
Harold J. Burstein, MD, PhD
- Role of Currently Available Epothilones in Resistant/Refractory Metastatic Breast Cancer
Hope S. Rugo, MD
- Emerging Microtubule-Targeting Agents: Strategies for Their Use in Resistant/Refractory Metastatic Breast Cancer
William J. Gradishar, MD
- Patient Case Studies
Hope S. Rugo, MD
This CME/CE activity is designed for oncologists and other clinicians who specialize in and care for patients with breast cancer.
The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with breast cancer.
- Utilizing an understanding of the molecular basis of breast cancer, evaluate and differentiate the mechanisms of action of microtubule-targeting agents, such as epothilones, taxanes, and vinca alkaloids, on microtubules and cell cycle arrest.
- Formulate future treatment strategies for women with local recurrent and metastatic breast cancer, especially those with resistant/refractory disease, incorporating the use of newer microtubule-targeting agents, such as epothilones, based on an understanding of the efficacy and safety of these agents as well as dosing schedules.
- Evaluate patients considered appropriate for, and who will benefit from, newer microtubule-targeting agents, including epothilones and vinca alkaloids, based on knowledge of the mechanism of action of epothilones and their efficacy and safety data.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
EduPro Resources LLC is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider Number P208-8/08-11.
EduPro Resources LLC is also an approved provider by the California Board of Registered Nursing, Provider Number
This activity is accredited for 1.3 contact hours.
Accreditation refers to educational content only and does not imply endorsement of products by NJSNA, ANCC, CBRN, or EduPro Resources LLC.
This activity is co-provided by Projects In Knowledge and EduPro Resources LLC.
CE Information: Pharmacists
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the program, for 1 contact hour (0.1 CEU) is 052-000-08-039-H01-P.
Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards of Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).
Harold J. Burstein, MD, PhD, has indicated that he has no real or apparent conflicts of interest to report. Dr. Burstein will not reference any unlabeled/unapproved uses of drugs or devices in his presentation.
William J. Gradishar, MD, has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the Speakers Bureau of and is on the Advisory Board of Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, Genentech Inc, Genomic Health, Inc and Novartis Pharmaceuticals Corporation. Dr. Gradishar will be discussing novel therapies for the treatment of advanced or metastatic breast cancer, some or all of which may be unlabeled or unapproved for use in the treatment of patients with advanced or metastatic breast cancer.
Hope S. Rugo, MD, has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc and Roche Pharmaceuticals; is on the speakers bureau for AstraZeneca PLC and Genomic Health, Inc; and is on the Advisory Board of Merck & Co, Inc. Dr. Rugo will be discussing novel treatments for treatment of advanced or metastatic breast cancer, some or all of which may be unlabeled or unapproved for use in the treatment of patients with advanced or metastatic breast cancer.
Peer Reviewer has no significant relationships to disclose.
Projects In Knowledge’s staff members have no significant relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.
This independent CME/CE activity is supported by an educational grants from Bristol-Myers Squibb, Genentech BioOncology, and Novartis Pharmaceuticals Corporation.
Requires Flash 8 or higher
and high-speed internet